^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CCT196969

i
Other names: CCT196969
Company:
Institute of Cancer Research, The University of Manchester
Drug class:
pan-RAF inhibitor, SRC-family kinase (SFK) inhibitor
2years
CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells. (PubMed, PLoS One)
Furthermore, CCT196969 inhibited viability in two B-Raf Proto-Oncogene (BRAF) inhibitor resistant metastatic melanoma cell lines. Further in vivo studies should be performed to determine the treatment potential of CCT196969 in patients with treatment-naïve and resistant melanoma brain metastasis.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
CCT196969